23% organic growth for record Q1 sales Margins held back by component situation Trades at 11-8x our...
Q1 operatating EBITA margin of -1.3% (ABGSCe 0.2%) Estimate visibility low on cancellation of guidan...
Redeye sees a Q1 report with the increased transparency regarding Bidbrain as the highlight.
Q1’22 EBITDA in line with our expectation We leave ’22e-’23e EBITDA roughly unchanged Maintain SEK 6...
Redeye returns with a more in-depth take on the Q1 report and discusses some of the key take-aways a...
Thinc Jetty redovisade idag en preliminär omsättningssiffra på 84,1 miljoner kronor för första kvart...
Redeye comments on Invisio’s Q1 results which came in weaker than expected mainly due to delay in de...
Bolagets kampanj över påsk lyckad Omsättningen i Q1 uppgick till 24,5 mkr vs vårt estimat om 21,7 mk...
Sales +10% vs. ABG & adj. EBIT margin 2% vs. ABG 4% Small negative GM and positive NRI adjustments ...
Odramatiskt kvartal men med styrketecken Karolinska Development redovisar ett substansvärde om 1306 ...
Aspo’s Q1 results clearly topped estimates, however the previous full-year guidance is retained for ...
Suominen’s Q1 results landed relatively close to estimates, although on the softer side.
Redeye reevaluates Alligator Bioscience ahead of its first efficacy readout from mitazalimab later t...
Net sales were 17% above consensus in Q1. Comparable operating profit was even 82% above market (Inf...
Temporary cost savings behind strong profitability in Q2 Positive L-T revisions from acquisitions Un...
Redeye adjusts the short-term estimates downward due to a slightly more challenging business environ...
Redeye comments on Lipigon’s announced rights issue and provides a new preliminary valuation.
Redeye comments on the Q1 report, which offered few surprises.
Suominen’s Q1 EBITDA was weak, as expected, due to the high inventory levels at some of Suominen’s k...
Addvise, en nischförvärvare av medicintekniska bolag, har inlett 2022 med hög förvärvad tillväxt och...
